For a scientific overview of the microbiome, the difference between GLP-1 agonist drugs and microbial approaches to regulating GLP-1, and the role GLP-1 plays in helping to maintain a healthy weight, please refer to the white paper: Harnessing GLP-1 in the digestive tract for better metabolic health
In MOMPOD, there was again no difference in primary composite neonatal outcomes, maternal weight gain or insulin use compared with placebo
Lixisenatide, a once-daily prandial glucagon-like peptide-1 receptor agonist for the treatment of adults with type 2 diabetes
Understanding and Managing Side Effects of GLP-1 Medications GLP-1 medications are effective for weight loss and metabolic health, but they can come with side effects
It can be difficult for consumers to tell the difference or trust the quality of the obesity drugs they're buying
We intentionally avoid bulking agents so the solids correspond predominantly to the target peptide, which simplifies mass-based calculations during method development